FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171600371> ?p ?o ?g. }

• W2171600371 endingPage "AB268" @default.
• W2171600371 startingPage "AB268" @default.
• W2171600371 abstract "RationaleThe house dust mite (HDM) SLIT-tablet (ALK, Denmark) has been shown to significantly reduce HDM allergic rhinitis (AR) symptoms in the MERIT trial, which met its primary endpoint (EAACI 2014, Abstr 415,417). To investigate the effect in AR in different subpopulations, we present a subgroup analysis that compares the efficacy of the HDM SLIT-tablet on rhinitis symptoms and medication use in subjects with asthma versus no asthma and mono- versus polysensitised subjects.MethodsMERIT (EudraCT no.2011-002277-38) was a double-blind, placebo-controlled, multi-centre phase III trial including 992 adults with moderate to severe HDM AR despite having received symptomatic treatment. Subjects were randomised 1:1:1 to 1 year of daily treatment with placebo, 6 SQ-HDM or 12 SQ-HDM. The primary endpoint was the total combined rhinitis score (TCRS, sum of rhinitis symptom and medication score) during the last 8 weeks of the treatment. A subgroup analysis was pre-specified in the protocol with respect to differences in average TCRS from placebo depending on asthma status and allergen sensitisation type (not adjusted for multiplicity).ResultsThe analysis showed that differences in average TCRS between active treatment (6 SQ-HDM, 12 SQ-HDM) and placebo were not statistically significant between any of the subgroups (asthma/no-asthma, p=0.81, mono-/polysensitised, p=0.74). Treatment was well-tolerated in all subgroups.ConclusionsThe subgroup analysis showed that there was no statistically significant difference between the effect of the active treatment in reducing HDM AR symptoms in subjects with asthma versus no asthma and mono- versus polysensitised subjects, supporting the use of the HDM SLIT-tablet in these subpopulations. RationaleThe house dust mite (HDM) SLIT-tablet (ALK, Denmark) has been shown to significantly reduce HDM allergic rhinitis (AR) symptoms in the MERIT trial, which met its primary endpoint (EAACI 2014, Abstr 415,417). To investigate the effect in AR in different subpopulations, we present a subgroup analysis that compares the efficacy of the HDM SLIT-tablet on rhinitis symptoms and medication use in subjects with asthma versus no asthma and mono- versus polysensitised subjects. The house dust mite (HDM) SLIT-tablet (ALK, Denmark) has been shown to significantly reduce HDM allergic rhinitis (AR) symptoms in the MERIT trial, which met its primary endpoint (EAACI 2014, Abstr 415,417). To investigate the effect in AR in different subpopulations, we present a subgroup analysis that compares the efficacy of the HDM SLIT-tablet on rhinitis symptoms and medication use in subjects with asthma versus no asthma and mono- versus polysensitised subjects. MethodsMERIT (EudraCT no.2011-002277-38) was a double-blind, placebo-controlled, multi-centre phase III trial including 992 adults with moderate to severe HDM AR despite having received symptomatic treatment. Subjects were randomised 1:1:1 to 1 year of daily treatment with placebo, 6 SQ-HDM or 12 SQ-HDM. The primary endpoint was the total combined rhinitis score (TCRS, sum of rhinitis symptom and medication score) during the last 8 weeks of the treatment. A subgroup analysis was pre-specified in the protocol with respect to differences in average TCRS from placebo depending on asthma status and allergen sensitisation type (not adjusted for multiplicity). MERIT (EudraCT no.2011-002277-38) was a double-blind, placebo-controlled, multi-centre phase III trial including 992 adults with moderate to severe HDM AR despite having received symptomatic treatment. Subjects were randomised 1:1:1 to 1 year of daily treatment with placebo, 6 SQ-HDM or 12 SQ-HDM. The primary endpoint was the total combined rhinitis score (TCRS, sum of rhinitis symptom and medication score) during the last 8 weeks of the treatment. A subgroup analysis was pre-specified in the protocol with respect to differences in average TCRS from placebo depending on asthma status and allergen sensitisation type (not adjusted for multiplicity). ResultsThe analysis showed that differences in average TCRS between active treatment (6 SQ-HDM, 12 SQ-HDM) and placebo were not statistically significant between any of the subgroups (asthma/no-asthma, p=0.81, mono-/polysensitised, p=0.74). Treatment was well-tolerated in all subgroups. The analysis showed that differences in average TCRS between active treatment (6 SQ-HDM, 12 SQ-HDM) and placebo were not statistically significant between any of the subgroups (asthma/no-asthma, p=0.81, mono-/polysensitised, p=0.74). Treatment was well-tolerated in all subgroups. ConclusionsThe subgroup analysis showed that there was no statistically significant difference between the effect of the active treatment in reducing HDM AR symptoms in subjects with asthma versus no asthma and mono- versus polysensitised subjects, supporting the use of the HDM SLIT-tablet in these subpopulations. The subgroup analysis showed that there was no statistically significant difference between the effect of the active treatment in reducing HDM AR symptoms in subjects with asthma versus no asthma and mono- versus polysensitised subjects, supporting the use of the HDM SLIT-tablet in these subpopulations." @default.
• W2171600371 created "2016-06-24" @default.
• W2171600371 creator A5022454023 @default.
• W2171600371 creator A5025157783 @default.
• W2171600371 creator A5031654532 @default.
• W2171600371 creator A5076184678 @default.
• W2171600371 date "2015-02-01" @default.
• W2171600371 modified "2023-09-27" @default.
• W2171600371 title "The HDM Slit-Tablet Reduces Symptoms of House Dust Mite Allergic Rhinitis Independently of Asthma Status and Allergen Sensitisation Type; A Subgroup Analysis of Results from a Dbpc Phase III Trial (MERIT)" @default.
• W2171600371 doi "https://doi.org/10.1016/j.jaci.2014.12.1816" @default.
• W2171600371 hasPublicationYear "2015" @default.
• W2171600371 type Work @default.
• W2171600371 sameAs 2171600371 @default.
• W2171600371 citedByCount "0" @default.
• W2171600371 crossrefType "journal-article" @default.
• W2171600371 hasAuthorship W2171600371A5022454023 @default.
• W2171600371 hasAuthorship W2171600371A5025157783 @default.
• W2171600371 hasAuthorship W2171600371A5031654532 @default.
• W2171600371 hasAuthorship W2171600371A5076184678 @default.
• W2171600371 hasBestOaLocation W21716003711 @default.
• W2171600371 hasConcept C126322002 @default.
• W2171600371 hasConcept C142724271 @default.
• W2171600371 hasConcept C168563851 @default.
• W2171600371 hasConcept C187960798 @default.
• W2171600371 hasConcept C203014093 @default.
• W2171600371 hasConcept C203092338 @default.
• W2171600371 hasConcept C204787440 @default.
• W2171600371 hasConcept C207480886 @default.
• W2171600371 hasConcept C27081682 @default.
• W2171600371 hasConcept C2776042228 @default.
• W2171600371 hasConcept C2778166374 @default.
• W2171600371 hasConcept C2780510475 @default.
• W2171600371 hasConcept C44249647 @default.
• W2171600371 hasConcept C71924100 @default.
• W2171600371 hasConceptScore W2171600371C126322002 @default.
• W2171600371 hasConceptScore W2171600371C142724271 @default.
• W2171600371 hasConceptScore W2171600371C168563851 @default.
• W2171600371 hasConceptScore W2171600371C187960798 @default.
• W2171600371 hasConceptScore W2171600371C203014093 @default.
• W2171600371 hasConceptScore W2171600371C203092338 @default.
• W2171600371 hasConceptScore W2171600371C204787440 @default.
• W2171600371 hasConceptScore W2171600371C207480886 @default.
• W2171600371 hasConceptScore W2171600371C27081682 @default.
• W2171600371 hasConceptScore W2171600371C2776042228 @default.
• W2171600371 hasConceptScore W2171600371C2778166374 @default.
• W2171600371 hasConceptScore W2171600371C2780510475 @default.
• W2171600371 hasConceptScore W2171600371C44249647 @default.
• W2171600371 hasConceptScore W2171600371C71924100 @default.
• W2171600371 hasIssue "2" @default.
• W2171600371 hasLocation W21716003711 @default.
• W2171600371 hasOpenAccess W2171600371 @default.
• W2171600371 hasPrimaryLocation W21716003711 @default.
• W2171600371 hasRelatedWork W1991336296 @default.
• W2171600371 hasRelatedWork W2037019085 @default.
• W2171600371 hasRelatedWork W2049326507 @default.
• W2171600371 hasRelatedWork W2092683273 @default.
• W2171600371 hasRelatedWork W2112795145 @default.
• W2171600371 hasRelatedWork W2152722283 @default.
• W2171600371 hasRelatedWork W2159856790 @default.
• W2171600371 hasRelatedWork W2333143909 @default.
• W2171600371 hasRelatedWork W2404949638 @default.
• W2171600371 hasRelatedWork W2619197634 @default.
• W2171600371 hasVolume "135" @default.
• W2171600371 isParatext "false" @default.
• W2171600371 isRetracted "false" @default.
• W2171600371 magId "2171600371" @default.
• W2171600371 workType "article" @default.